CCN2 and Myocardial fibrosis: In a rabbit HFrEF model, CCM therapy reduced cardiac expression of connective tissue growth factor and galectin-3 (a pro-fibrotic marker involved in myocardial structural remodeling) with a reduction of myocardial fibrosis [11].